Showing results (221-230 of 229) with videos related to
Sort By:
Pageof 23
You have reached the last page of results.This site can display upto 229 results.
Nature Communications|September 3, 2024
Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cellsRachid Safi, Suzanne E Wardell, Paige Watkinson, et al.Science Signaling|December 25, 2014
Systematic identification of signaling pathways with potential to confer anticancer drug resistanceColin A Martz, Kathleen A Ottina, Katherine R Singleton, et al.NPJ Breast Cancer|January 3, 2025
Effects of RARα ligand binding domain mutations on breast fibroepithelial tumor function and signalingXi Xiao Huang, Ley Moy Ng, Po-Hsien Lee, et al.Scientific Data|November 2, 2019
The Signaling Pathways Project, an integrated 'omics knowledgebase for mammalian cellular signaling pathwaysScott A Ochsner, David Abraham, Kirt Martin, et al.Journal of Medicinal Chemistry|March 23, 2018
Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast CancerGeorge S Tria, Tinya Abrams, Jason Baird, et al.ACS Nano|May 22, 2012
Rapid transformation of protein-caged nanomaterials into microbubbles as bimodal imaging agentsCheng-An J Lin, Wen-Kai Chuang, Zih-Yun Huang, et al.Cells|January 21, 2023
SGC-CAMKK2-1: A Chemical Probe for CAMKK2Carrow Wells, Yi Liang, Thomas L Pulliam, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2025
Discovery of BMS-986365, a first-in-class dual androgen receptor ligand-directed degrader (AR LDD) and antagonist, for the treatment of advanced prostate cancerSurendra Nayak, John D Norris, Massimo Ammirante, et al.Journal of Medicinal Chemistry|July 10, 2026
Discovery of Potential First-in-Class Dual Ligand-Directed Degrader and Antagonist of the Androgen Receptor: BMS-986365Deborah S Mortensen, Surendra Nayak, Veronique Plantevin-Krenitsky, et al.Pageof 23